Patent Grant
11891603
The instant application contains a Sequence Listing which has been filed electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 15, 2020, is named 45532-746-301_SL.txt and is 92,718 bytes in size.
Disruption of alternative splicing underlies many diseases, and modulation of splicing using antisense oligonucleotides can have therapeutic implications. Splice-switching antisense oligonucleotides (SSOs) are emerging treatments for neuromuscular diseases, with several SSOs currently undergoing clinical trials for conditions such as spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD), where antisense-mediated exon skipping can restore the open reading frame and allow the synthesis of partly or wholly functional proteins instead of non-functional ones.
Duchenne muscular dystrophy (DMD) is one of the most prevalent lethal genetic disorders in boys worldwide, with an incidence of approx. 1 in 3,600-9,337 live male births. DMD is caused by the absence of dystrophin protein due to mutations in the dystrophin (DMD) gene. The gene encoding the protein contains 79 exons spread out over more than 2 million nucleotides of DNA. Any exonic mutation that changes the reading frame of the exon, or introduces a stop codon, or is characterized by removal of an entire out of frame exon or exons or duplications of one or more exons has the potential to disrupt production of functional dystrophin, resulting in DMD. A less severe form of muscular dystrophy, Becker muscular dystrophy (BMD) has been found to arise where a mutation, typically a deletion of one or more exons, results in a correct reading frame along the entire dystrophin transcript, such that translation of mRNA into protein is not prematurely terminated. If the joining of the upstream and downstream exons in the processing of a mutated dystrophin pre-mRNA maintains the correct reading frame of the gene, the result is an mRNA coding for a protein with a short internal deletion that retains some activity resulting in a Becker Page 1 Header phenotype. Deletions of an exon or exons which do not alter the reading frame of a dystrophin protein give rise to a BMD phenotype, whereas an exon deletion that causes a frame-shift will give rise to DMD (MonAc0, Bertelson et al. 1988). In general, dystrophin mutations including point mutations and exon deletions that change the reading frame and thus interrupt proper protein translation result in DMD.
Currently one of the most promising therapeutic avenues is exon skipping using antisense oligonucleotides (AOs). Exon skipping can restore the reading frame by removing the mutant exon and/or its flanking exon(s) from the DMD pre-mRNA, enabling the production of truncated but partly-functional dystrophin protein. A majority of DMD patients harbour deletion mutations and 20% of these are amenable to exon 51 skipping.
In September 2016, the US Food and Drug Administration (FDA) conditionally approved the first DMD antisense drug, eteplirsen (Exondys 51), which was developed to exclude exon 51 from mutant DMD. Eteplirsen is an AO modified with a phosphorodiamidate morpholino oligomer (morpholino or PMO), an antisense chemistry that has been well-established in terms of its safety and effectiveness. However, eteplirsen remains controversial as there is only weak evidence supporting the effectiveness of the drug, both in terms of restoring dystrophin protein to therapeutically beneficial levels, and improving clinical outcomes. The FDA has previously rejected another drug candidate for DMD exon 51 skipping: the 2′-O-methyl-phosphorothioate-based AO ‘drisapersen’. Although therapeutics must ensure the highest possible benefit for the lowest amount of risk, no significant improvements in muscle function were demonstrated upon treatment with drisapersen, and its use led to concerns over safety.
Therefore, exon skipping therapies currently face a major challenge in that their observed efficacy in patients has been very low despite the fact that significant therapeutic effects have been demonstrated in many animal studies.
Exon skipping efficiency is largely dependent on the AO target sequence: however, there has been little debate or discussion that the sequences targeted by eteplirsen and drisapersen might not be the optimal choices for exon skipping therapy. Several groups have undertaken large-scale AO screening efforts to determine effective AO sequences computationally and empirically. However, the exon skipping effectiveness of designed AOs has not been evaluated both quantitatively and statistically. Although restoring dystrophin protein expression is necessary to improve dystrophic muscle function, the ability of AOs to rescue dystrophin protein expression has not been reported with sufficient Page 2 Header methods of quantification in previous AO screening studies. Other studies have highly relied on RT-PCR from primary DMD muscle cells. It is remarkable that the AO sequences of eteplirsen and drisapersen were determined only within this context.
Thus, the effectiveness of exon 51 skipping therapy could be improved by selecting more optimal AO sequences, and by performing more rigorous AO screening using a more reliable and direct biological measure—such as rescued dystrophin protein in DMD—for validating the best antisense oligonucleotides to be taken forward in a clinical trial.
It is an aim of one or more aspects of the present invention to address one or more such problems in the art.
According to a first aspect of the present invention, there is provided an antisense oligonucleotide capable of binding to exon 51 of human dystrophin pre-mRNA, wherein binding of the antisense oligonucleotide takes place entirely within the region between 0 and +89 of the pre-mRNA sequence, and wherein the antisense oligonucleotide comprises at least 27 bases.
According to a second aspect of the present invention, there is provided a conjugate comprising an antisense oligonucleotide according to the first aspect and a carrier, wherein the carrier is conjugated to the antisense oligonucleotide.
According to a third aspect of the present invention, there is provided a cell loaded with a conjugate of the second aspect.
According to a fourth aspect of the present invention, there is provided a pharmaceutical composition comprising an antisense oligonucleotide according to the first aspect, and/or a conjugate according to the second aspect, and a pharmaceutically acceptable excipient. According to a fifth aspect of the present invention, there is provided a method of treating a muscular disorder in a subject, comprising administering an effective amount of an antisense oligonucleotide capable of binding to exon 51 of human dystrophin pre-mRNA to a subject, wherein binding of the antisense oligonucleotide takes place entirely within the region between 0 and +89 of the pre-mRNA sequence, and wherein the antisense oligonucleotide comprises at least 27 bases.
According to a sixth aspect of the present invention, there is provided an antisense oligonucleotide capable of binding to exon 51 of human dystrophin pre-mRNA for use in Page 3 Header the treatment of a muscular disorder in a subject, wherein binding of the antisense oligonucleotide takes place entirely within the region between 0 and +89 of the pre-mRNA sequence, and wherein the antisense oligonucleotide comprises at least 27 bases.
According to a seventh aspect of the present invention, there is provided a method of increasing human dystrophin protein expression in a cell comprising contacting the cell with an effective amount of an antisense oligonucleotide capable of binding to exon 51 of human dystrophin pre-mRNA, wherein binding of the antisense oligonucleotide takes place entirely within the region between 0 and +89 of the pre-mRNA sequence, and wherein the antisense oligonucleotide comprises at least 27 bases.
The inventors have developed a series of antisense oligonucleotides binding within the early region at 0 to +89 of exon 51 of the dystrophin pre-mRNA sequence and which have a longer than usual length of at least 27 bases, each having remarkable efficiency and effectiveness.
In order to produce the antisense oligonucleotides, the inventors performed a study which quantitatively evaluated the effectiveness of morpholino-based antisense oligonucleotides for exon 51 skipping using a systematic screening method involving in silico, in vitro, and in vivo tests.
The inventors carried out a combination screening using a computational analysis to predict exon skipping efficiency of designed antisense oligonucleotide sequences followed by in vitro tests of morpholino antisense oligonucleotides in immortalized DMD patient-derived muscle cell lines. This research revealed that the beginning of the human dystrophin exon 51 sequence is a very promising target region for inducing exon skipping, specifically the region of 0 to +89 of the sequence. This is notably different from the internal region targeted by the known eteplirsen and drisapersen antisense therapies.
The antisense oligonucleotides identified from this region were then optimised for the most effective restoration of dystrophin production in muscle cells. Various factors were investigated, including the length of the antisense oligonucleotides. Surprisingly, the inventors found that antisense oligonucleotides binding in this early region are more effective when they are longer than many of the known antisense oligonucleotide sequences against exon 51. Specifically, the inventors identified an upward trend correlating effectiveness with the length of the antisense oligonucleotide from 27 bases and Page 4 Header longer. The inventors have shown that just a few bases difference means the antisense oligonucleotide has a significantly different efficiency. As demonstrated herein, 30-mer antisense oligonucleotides work up to 1.5-fold better than a 25-mer of the same sequence (42% vs. 65% skipping efficiency). Without wishing to be bound by theory, this may be because longer sequences can be more specific to the target sequence and less likely to cause off-target effects.
It is demonstrated herein that the inventors' optimisation of these identified antisense oligonucleotide sequences has enabled efficiency in exon 51 skipping and in rescuing dystrophin protein to increase by up to more than 12-fold and 7-fold respectively compared to the industry standard ‘eteplirsen’ sequence. Furthermore, statistically significant in vivo exon 51 skipping by the most effective antisense oligonucleotide identified through these in vitro screenings was confirmed using transgenic mice harbouring the human DMD gene, which has never been shown for the eteplirsen or drisapersen antisense oligonucleotides. Accordingly, the antisense oligonucleotides described herein are shown to provide an effective therapy and treatment for muscular disorders, especially for the treatment of DMD. These antisense oligonucleotides are not only providing an alternative therapy into a field of medicine in which only one such drug has been approved for market. They also provide an improved option for treatment which is several times more effective at increasing dystrophin protein expression. This is expected to provide a viable option for treatment for those suffering from DMD and other muscular disorders with strong evidence to support the effectiveness of the therapy.
For the avoidance of doubt, and in order to clarify the way in which the present disclosure is to be interpreted, certain terms used in accordance with the present invention will now be defined further.
The invention includes any combination of the aspects and features described except where such a combination is clearly impermissible or expressly avoided.
It is noted that where aspects of the invention may refer methods or uses including an antisense oligonucleotide, this may also include a conjugate or pharmaceutical composition comprising an antisense oligonucleotide as defined herein.
The section headings used herein are for organisational purposes only and are not to be construed as limiting the subject matter described.
Antisense Oligonucleotide
The present invention relates to antisense oligonucleotides having a length of at least 27 bases that bind to exon 51 of human dystrophin pre-mRNA within the region of 0 to +89 which can be used to treat muscular disorders.
Suitably, ‘antisense oligonucleotides’ may be referred to herein as ‘AOs’ or ‘oligos’ or ‘oligomers’.
Suitably the antisense oligonucleotide induces skipping of exon 51 of the human dystrophin gene.
Suitably the antisense oligonucleotide increases skipping of exon 51 of the human dystrophin gene.
Suitably the antisense oligonucleotide allows expression of functional human dystrophin protein.
Suitably the antisense oligonucleotide increases expression of functional human dystrophin protein.
Suitably, the antisense oligonucleotide comprises at least 28 bases, suitably at least 29 bases, suitably at least 30 bases.
Suitably, the antisense oligonucleotide comprises between 27 and 30 bases. In one embodiment, the antisense oligonucleotide comprises 30 bases.
In one embodiment, the antisense oligonucleotide consists of 30 bases.
Suitably, the binding of the antisense oligonucleotide takes place entirely within the region between 0 and +88, 0 and +87, 0 and +86, 0 and +85, 0 and +84, 0 and +83, 0 and +82, 0 and +81, 0 and +80, 0 and +79, 0 and +78 of the pre-mRNA sequence.
In one embodiment, the binding of the antisense oligonucleotide takes place entirely within the region between 0 and +78 of the pre-mRNA sequence.
Suitably, the antisense oligonucleotide comprises at least 27 bases of one of the following sequences: SEQ ID NO.1 (Ac0), SEQ ID NO.2 (Ac5), SEQ ID NO.3 (Ac26), SEQ ID NO.4 (Ac30), or SEQ ID NO.5 (Ac48).
Suitably, the antisense oligonucleotide comprises at least 28 bases of one of the following sequences: SEQ ID NO.1 (Ac0), SEQ ID NO.2 (Ac5), SEQ ID NO.3 (Ac26), SEQ ID NO.4 (Ac30), or SEQ ID NO.5 (Ac48).
Suitably, the antisense oligonucleotide comprises at least 29 bases of one of the following sequences: SEQ ID NO.1 (Ac0), SEQ ID NO.2 (Ac5), SEQ ID NO.3 (Ac26), SEQ ID NO.4 (Ac30), or SEQ ID NO.5 (Ac48).
Suitably, the antisense oligonucleotide comprises at least 27 contiguous bases of one of the following sequences: SEQ ID NO.1 (Ac0), SEQ ID NO.2 (Ac5), SEQ ID NO.3 (Ac26), SEQ ID NO.4 (Ac30), or SEQ ID NO.5 (Ac48).
Suitably, the antisense oligonucleotide comprises at least 28 contiguous bases of one of the following sequences: SEQ ID NO.1 (Ac0), SEQ ID NO.2 (Ac5), SEQ ID NO.3 (Ac26), SEQ ID NO.4 (Ac30), or SEQ ID NO.5 (Ac48).
Suitably, the antisense oligonucleotide comprises at least 29 contiguous bases of one of the following sequences: SEQ ID NO.1 (Ac0), SEQ ID NO.2 (Ac5), SEQ ID NO.3 (Ac26), SEQ ID NO.4 (Ac30), or SEQ ID NO.5 (Ac48).
Suitably, the antisense oligonucleotide shares at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with one of the following sequences: SEQ ID NO.1 (Ac0), SEQ ID NO.2 (Ac5), SEQ ID NO.3 (Ac26), SEQ ID NO.4 (Ac30), or SEQ ID NO.5 (Ac48).
Suitably, the antisense oligonucleotide shares between 90% and 100% identity with one of the following sequences: SEQ ID NO.1 (Ac0), SEQ ID NO.2 (Ac5), SEQ ID NO.3 (Ac26), SEQ ID NO.4 (Ac30), or SEQ ID NO.5 (Ac48).
Suitably, the antisense oligonucleotide shares at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% homology with one of the following sequences: SEQ ID NO.1 (Ac0), SEQ ID NO.2 (Ac5), SEQ ID NO.3 (Ac26), SEQ ID NO.4 (Ac30), or SEQ ID NO.5 (Ac48).
Suitably, the antisense oligonucleotide shares between 90% and 100% homology with one of the following sequences: SEQ ID NO.1 (Ac0), SEQ ID NO.2 (Ac5), SEQ ID NO.3 (Ac26), SEQ ID NO.4 (Ac30), or SEQ ID NO.5 (Ac48).
Suitably, the antisense oligonucleotide may comprise a variant antisense oligonucleotide which differs from one of the following sequences: SEQ ID NO.1 (Ac0), SEQ ID NO.2 (Ac5), SEQ ID NO.3 (Ac26), SEQ ID NO.4 (Ac30), or SEQ ID NO.5 (Ac48) by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 bases.
Suitably, the antisense oligonucleotide may comprise a variant antisense oligonucleotide which differs from one of the following sequences: SEQ ID NO.1 (Ac0), SEQ ID NO.2 (Ac5), SEQ ID NO.3 (Ac26), SEQ ID NO.4 (Ac30), or SEQ ID NO.5 (Ac48) by up to 3 bases. Suitably, the antisense oligonucleotide may comprise a variant antisense oligonucleotide which differs from one of the following sequences: SEQ ID NO.1 (Ac0), SEQ ID NO.2 (Ac5), SEQ ID NO.3 (Ac26), SEQ ID NO.4 (Ac30), or SEQ ID NO.5 (Ac48) by up to 2 bases. Suitably, the antisense oligonucleotide may comprise a variant antisense oligonucleotide which differs from one of the following sequences: SEQ ID NO.1 (Ac0), SEQ ID NO.2 (Ac5), SEQ ID NO.3 (Ac26), SEQ ID NO.4 (Ac30), or SEQ ID NO.5 (Ac48) by a single base. Suitably, the antisense oligonucleotide comprises one of the following sequences: SEQ ID NO.1 (Ac0), SEQ ID NO.2 (Ac5), SEQ ID NO.3 (Ac26), SEQ ID NO.4 (Ac30), or SEQ ID NO.5 (Ac48).
Suitably, the antisense oligonucleotide consists of one of the following sequences: SEQ ID NO.1 (Ac0), SEQ ID NO.2 (Ac5), SEQ ID NO.3 (Ac26), SEQ ID NO.4 (Ac30), or SEQ ID NO.5 (Ac48).
Suitably, the antisense oligonucleotide comprises SEQ ID NO.1 (Ac0) or SEQ ID NO.5 (Ac48).
In one embodiment, the antisense oligonucleotide comprises SEQ ID NO.1 (Ac0).
Suitably, the antisense oligonucleotide consists of SEQ ID NO.1 (Ac0) or SEQ ID NO.5 (Ac48).
In one embodiment, the antisense oligonucleotide consists of SEQ ID NO.1 (Ac0).
It will be appreciated that the invention may further include aspects directed towards each of the individual antisense oligonucleotide sequences listed in Table 3 i.e. an antisense oligonucleotide comprising or consisting of any of the sequences listed in Table 3. Furthermore, in accordance with the second aspect of the invention, a conjugate comprising an antisense oligonucleotide as listed in Table 3 is envisaged. Furthermore a pharmaceutical composition in accordance with the fourth aspect of the invention,
comprising an antisense oligonucleotide as listed in Table 3 or a conjugate thereof is envisaged. Furthermore a medical use in accordance with the fifth aspect of the invention, comprising an antisense oligonucleotide as listed in Table 3 for the treatment of a muscular disorder is envisaged. Furthermore a method of treatment in accordance with the sixth aspect comprising an antisense oligonucleotide as listed in Table 3 is envisaged. Furthermore a method of increasing human dystrophin protein expression in a cell in accordance with the seventh aspect comprising an antisense oligonucleotide as listed in Table 3 is envisaged.
Suitably, the antisense oligonucleotide is synthetic, and non-natural.
Suitably, the antisense oligonucleotide may be routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several manufacturers including, for example, Applied Biosystems (Foster City, Calif.). One method for synthesising oligonucleotides on a modified solid support is described in U.S. Pat. No. 4,458,066. Any other means for such synthesis known in the art may additionally or alternatively be employed.
Suitably, the antisense oligonucleotide is an antisense oligonucleotide analogue.
Suitably, the term ‘oligonucleotide analogue’ and ‘nucleotide analogue’ refer to any modified synthetic analogues of oligonucleotides or nucleotides respectively that are known in the art.
Suitable examples of oligonucleotide analogues include peptide nucleic acids (PNAs), morpholino oligonucleotides, phosphorothioate oligonucleotides, phosphorodithioate oligonucleotides, alkylphosphonate oligonucleotides, acylphosphonate oligonucleotides and phosphoramidite oligonucleotides.
Suitably, the antisense oligonucleotide comprises morpholino subunits. Suitably therefore, the antisense oligonucleotide is a morpholino antisense oligonucleotide.
Suitably, the antisense oligonucleotide comprises morpholino subunits linked together by phosphorus-containing linkages. Suitably therefore, the antisense oligonucleotide is a phosphoramidate or phosphorodiamidate morpholino antisense oligonucleotide.
The terms ‘morpholino antisense oligonucleotide’ or ?MO’ (phosphoramidate or phosphorodiamidate morpholino oligonucleotide) refer to an antisense oligonucleotide Page 9 Header analog composed of morpholino subunit structures, where (i) the structures are linked together by phosphorus-containing linkages, suitably one to three atoms long, suitably two atoms long, and suitably uncharged or cationic, joining the morpholino nitrogen of one subunit to a 5′ exocyclic carbon of an adjacent subunit, and (ii) each morpholino ring bears a purine or pyrimidine base-pairing moiety effective to bind, by base specific hydrogen bonding, to a base in a polynucleotide.
Suitably, the antisense oligonucleotide comprises phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of an adjacent subunit.
Suitably, the antisense oligonucleotide comprises phosphorus-containing intersubunit linkages in accordance with the following structure (I):
wherein:
Y1 is 0, S, NH—, or —CH2-;
Z is 0 or S;
Pj is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide; and X is fluoro, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted thioalkoxy, amino, optionally substituted alkylamino, or optionally substituted heterocyclyl.
Optionally, variations can be made to the intersubunit linkage as long as the variations do not interfere with binding or activity. For example, the oxygen attached to phosphorus may be substituted with sulfur (thiophosphorodiamidate). The 5′ oxygen may be substituted with amino or lower alkyl substituted amino. The pendant nitrogen attached to the phosphorus may be unsubstituted, monosubstituted, or disubstituted with (optionally substituted) lower alkyl.
Suitably, the synthesis, structures, and binding characteristics of morpholino oligonucleotides are detailed in U.S. Pat. Nos. 5,698,685, 5,217,866, 5,142,047, 5,034,506, 5,166,315, 5,521,063, and 5,506,337, and PCT Appn. No. PCT/US07/11435.
Binding of the Antisense Oligonucleotide
The present invention relates to an antisense oligonucleotide capable of binding within the region 0 to +89 of exon 51 of human dystrophin pre-mRNA.
By ‘capable of binding’ it is meant that the antisense oligonucleotide comprises a sequence with is able to bind to human dystrophin pre-mRNA in the region stated.
Suitably, the antisense oligonucleotide is complementary to a sequence of human dystrophin pre-mRNA in the region stated.
Suitably, the antisense oligonucleotide comprises a sequence which is complementary to a sequence of human dystrophin pre-mRNA in the region stated.
The antisense oligonucleotide and a sequence within the region 0 to +89 of exon 51 of human dystrophin pre-mRNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other and thereby cause exon skipping, suitably exon skipping of exon 51. Thus, ‘hybridisable’ and ‘complementary’ are terms which are used to indicate a sufficient degree of complementarity or pairing such that stable and specific binding occurs between the antisense oligonucleotide and a sequence within region 0 to +89 of exon 51 of human dystrophin pre-mRNA. Suitably, the antisense oligonucleotide is sufficiently hybridisable and/or complementary to a sequence within region 0 to +89 of exon 51 of human dystrophin pre-mRNA to induce exon skipping, suitably exon skipping of exon 51. Suitably, the antisense oligonucleotide may not be 100% complementary to a sequence within region of 0 to +89 of exon 51 of human dystrophin pre-mRNA. However, suitably the antisense oligonucleotide is sufficiently complementary to avoid non-specific binding.
Suitably, the antisense oligonucleotide is at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% at least 99% complementary to a sequence within the region 0 to +89 of exon 51 of human dystrophin pre-mRNA.
It is understood that in order for the antisense oligonucleotide to be capable of binding, it does not require that the entire length of the antisense oligonucleotide binds to the human dystrophin pre-mRNA. It will be appreciated that a portion of the antisense oligonucleotide Page 11 Header may not bind to the human dystrophin pre-mRNA, for example the 5′ or the 3′ ends of the antisense oligonucleotide. However, in accordance with the first aspect, the parts of the antisense oligonucleotide which are bound to the human dystrophin pre-mRNA must fall within the region of 0 to +89 of exon 51.
Suitably, therefore, the antisense oligonucleotide is hybridisable to a sequence within the region of 0 to +89 of exon 51 of human dystrophin pre-mRNA. Suitably, the antisense oligonucleotide is sufficiently hybridisable to a sequence within the region of 0 to +89 of exon 51 of human dystrophin pre-mRNA to cause exon skipping of exon 51.
Human Dystrophin
The present invention relates to a therapeutic antisense oligonucleotide for use in the treatment of muscular disorders, particularly dystrophin disorders such as DMD.
Dystrophin is a rod-shaped cytoplasmic protein, and a vital part of the protein complex that connects the cytoskeleton of a muscle fibre to the surrounding extracellular matrix through the cell membrane.
Dystrophin protein contains multiple functional domains. The DMD gene, encoding the dystrophin protein, is one of the longest known human genes covering 2.3 megabases (0.08% of the human genome) at locus Xp21. The primary transcript in muscle measures about 2,100 kilobases and takes 16 hours to transcribe; the mature mRNA measures 14.0 kilobases. The 79-exon muscle transcript codes for a protein of 3685 amino acid residues. Dystrophin protein contains an actin binding domain and a central rod domain. This large central domain is formed by 24 spectrin-like triple-helical elements of about 109 amino acids, which have homology to alpha-actinin and spectrin. The repeats are typically interrupted by four proline-rich non-repeat segments, also referred to as hinge regions. Each repeat is encoded by two exons, typically interrupted by an intron between amino acids 47 and 48 in the first part of alpha-helix 2. The other intron is found at different positions in the repeat, usually scattered over helix 3. Dystrophin also contains a cysteine-rich domain including a cysteine-rich segment (i.e., 15 Cysteines in 280 amino acids).
In normal cases, the amino-terminus of dystrophin binds to F-actin and the carboxy-terminus binds to the dystrophin-associated protein complex (DAPC) at the sarcolemma. The DAPC includes the dystroglycans, sarcoglycans, integrins and caveolin, and mutations in any of these components cause autosomally inherited muscular dystrophies. Normal skeletal muscle tissue contains only small amounts of dystrophin (about 0.002% of total muscle protein), but its absence (or abnormal expression) leads to the development of a Page 12 Header severe and currently incurable symptoms most readily characterized by several aberrant intracellular signaling pathways that ultimately yield pronounced myofiber necrosis as well as progressive muscle weakness and fatigability. The DAPC is destabilized when dystrophin is absent, which results in diminished levels of the member proteins, and in turn leads to progressive fibre damage and membrane leakage. In various forms of muscular dystrophy, such as Duchenne's muscular dystrophy (DMD) and Becker's muscular dystrophy (BMD), muscle cells produce an altered and functionally defective form of dystrophin, or no dystrophin at all, mainly due to mutations in the gene sequence that lead to incorrect splicing. The predominant expression of the defective dystrophin protein, or the complete lack of dystrophin or a dystrophin-like protein, leads to rapid progression of muscle degeneration.
The mRNA encoding dystrophin in muscular dystrophy patients typically contains out-of-frame mutations (e.g. deletions, insertions or splice site mutations), resulting in frameshift or early termination of the translation process, so that in most muscle fibres no functional dystrophin is produced.
Suitably, the antisense oligonucleotide triggers exon skipping to restore the reading frame of the dystrophin mRNA. Suitably, the antisense oligonucleotide triggers exon skipping of exon 51 to restore the reading frame of the dystrophin mRNA. Suitably, restoration of the reading frame restores production of a partially functional dystrophin protein.
Suitably, the partially functional dystrophin is a truncated dystrophin protein.
Suitably, the truncated dystrophin protein is the same dystrophin protein produced in patients suffering from the less severe muscular disorder; BMD.
Muscular Disorder
The present invention relates to the use of therapeutic antisense oligonucleotides in the treatment of muscular disorders.
Suitably the muscular disorder is selected from any muscular disorder resulting from a genetic mutation.
Suitably the muscular disorder is selected from any muscular disorder resulting from a genetic mutation in a gene associated with muscle function.
Suitably the muscular disorder is selected from any muscular disorder resulting from a genetic mutation in the human dystrophin gene.
Suitably, the muscular disorder is selected from any muscular dystrophy disorder.
Suitably, the muscular disorder is selected from Duchenne muscular dystrophy, Becker muscular dystrophy, congenital muscular dystrophy, Distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral muscular dystrophy, Limb-girdle muscular dystrophy, Myotonic muscular dystrophy, Oculopharyngeal Muscular dystrophy. Suitably, the muscular disorder is Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD).
In one embodiment, the muscular disorder is DMD.
Carrier and Conjugate
The present invention also relates to a conjugate of the antisense oligonucleotide with a carrier.
Suitably, the carrier may comprise any molecule operable to transport the antisense oligonucleotide into a target cell, suitably into a muscle cell.
Suitable carriers may include; peptides, small molecule chemicals, polymers, nanoparticles, lipids, liposomes, exosomes or the like.
Suitably, the carrier is a peptide. The peptide may be selected from viral proteins such as VP22 (derived from herpes virus tegument protein), snake venom protein such as CyLOP-1 (derived from crotamin), cell adhesion glycoproteins such as pVEC (derived from murine vascular endothelial-cadherin protein), Penetratin (Antennapedia homeodomain), Tat (human immunodeficiency virus transactivating regulatory protein) or reverse Tat, for example.
Suitably, the peptide is a cell penetrating peptide.
Suitably, the peptide is an arginine-rich cell penetrating peptide.
The use of arginine-rich peptide carriers is particularly useful. Certain arginine based peptide carriers have been shown to be highly effective at delivery of antisense compounds into primary cells including muscle cells (Marshall, Oda et al. 2007; Jearawiriyapaisarn, Moulton et al. 2008; Wu, Moulton et al. 2008). Furthermore, compared to other peptides,
the arginine peptide carriers when conjugated to an antisense oligonucleotide, demonstrate an enhanced ability to alter splicing of several gene transcripts (Marshall, Oda et al. 2007). Suitably, the arginine-rich cell penetrating peptide may be selected from those carrier peptides described in WO2015075747, WO2013030569, WO2009147368, US20120289457, or US20160237426, for example.
In one embodiment, the arginine rich cell penetrating peptide is selected from those described in WO2013030569 or WO2009147368.
Suitably, the carrier has the capability of inducing cell penetration of the antisense oligonucleotide within at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of cells of a given cell culture population. Suitably, the carrier has the capability of inducing cell penetration of the antisense oligonucleotide within at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of muscle cells in a muscle cell culture.
Suitably, conjugation of the carrier to the antisense oligonucleotide may be at any position suitable for forming a covalent bond between the carrier and the antisense oligonucleotide or between the linker moiety and the antisense oligonucleotide. For example, conjugation of a carrier may be at the 3′ end of the antisense oligonucleotide. Alternatively, conjugation of a carrier to the antisense oligonucleotide may be at the 5′ end of the oligonucleotide. Alternatively, a carrier may be conjugated to the antisense oligonucleotide through any of the intersubunit linkages.
Suitably, the carrier is covalently coupled at its N-terminal or C-terminal residue to the 3′ or 5′ end of the antisense oligonucleotide.
Suitably, the carrier is coupled at its C-terminal residue to the 5′ end of the antisense oligonucleotide.
Optionally, where the antisense oligonucleotide comprises phosphorus-containing intersubunit linkages, and the carrier is a peptide, the peptide may be conjugated to the antisense oligonucleotide via a covalent bond to the phosphorous of the terminal linkage group.
Alternatively, when the carrier is a peptide, and the antisense oligonucleotide is a morpholino, the peptide may be conjugated to the nitrogen atom of the 3′ terminal morpholino group of the oligomer.
Optionally, the carrier may be conjugated to the antisense oligonucleotide via a linker moiety. Optionally, the linker moiety may comprise one or more of: an optionally substituted piperazinyl moiety, a beta alanine, glycine, proline, and/or a 6-aminohexanoic acid residue in any combination.
Alternatively, the carrier may be conjugated directly to the antisense oligonucleotide without a linker moiety.
Suitably the conjugate may further comprise a homing moiety.
Suitably, the homing moiety is selective for a selected mammalian tissue, i.e., the same tissue being targeted by the antisense oligonucleotide. Suitably, the homing moiety is selective for muscle tissue.
Suitably, the homing moiety is a homing peptide.
Suitable homing peptides are disclosed in ‘Effective Dystrophin Restoration by a Novel Muscle-Homing Peptide—Morpholino Conjugate in Dystrophin-Deficient mdx Mice’ Gao et Mol Ther. 2014 July; 22(7): 1333-1341, for example.
Suitably, the carrier peptide and the homing peptide may be formed as a chimeric fusion protein.
Suitably, the conjugate may comprise a chimeric peptide formed from a cell penetrating peptide and a muscle-specific homing peptide.
Optionally, the conjugate may be of the form: carrier peptide-homing peptide-antisense oligonucleotide or of the form: homing peptide-carrier peptide-antisense oligonucleotide. Suitably, the antisense oligonucleotide may be conjugated to a carrier that enhances the solubility of the antisense oligonucleotide. Suitably the solubility in an aqueous medium. Suitably, a carrier that enhances solubility may be conjugated to the antisense oligonucleotide in addition to a carrier operable to transport the antisense oligonucleotide. Suitably, the carrier that enhances solubility and the carrier that transports the antisense oligonucleotide may be formed as a chimeric fusion protein.
Suitable carriers that enhance the solubility of an antisense oligonucleotide are polymers, such as polyethylene glycol, or triethylene glycol.
Pharmaceutically Acceptable Excipient
The present invention further relates to a pharmaceutical composition comprising the antisense oligonucleotide of the invention or a conjugate thereof, further comprising one or more pharmaceutically acceptable excipients.
Suitably, the pharmaceutical composition is prepared in a manner known in the art (as described in Remingtons Pharmaceutical Sciences, Mack Publ. Co., Easton, Pa. (1985)), with pharmaceutically inert inorganic and/or organic excipients being used. The term ‘pharmaceutically acceptable’ refers to molecules and compositions that are physiologically tolerable and do not typically produce an allergic or similarly untoward reaction when administered to a patient.
Suitably, the pharmaceutical composition may be formulated as a pill, tablet, coated tablet, hard gelatin capsule, soft gelatin capsule and/or suppository, solution and/or syrup, injection solution, microcapsule, implant and/or rod, and the like.
In one embodiment, the pharmaceutical composition may be formulated as an injection solution.
Suitably, pharmaceutically acceptable excipients for preparing pills, tablets, coated tablets and hard gelatin capsules may be selected from any of: Lactose, corn starch and/or derivatives thereof, talc, stearic acid and/or its salts, etc.
Suitably, pharmaceutically acceptable excipients for preparing soft gelatin capsules and/or suppositories may be selected from fats, waxes, semisolid and liquid polyols, natural and/or hardened oils, etc.
Suitably, pharmaceutically acceptable excipients for preparing solutions and/or syrups may be selected from water, sucrose, invert sugar, glucose, polyols, etc.
Suitably, pharmaceutically acceptable excipients for preparing injection solutions may be selected from water, saline, alcohols, glycerol, polyols, vegetable oils, etc.
Suitably, pharmaceutically acceptable excipients for preparing microcapsules, implants and/or rods may be selected from mixed polymers such as glycolic acid and lactic acid or the like.
In addition, the pharmaceutical composition may comprise a liposome formulation which are described in N. Weiner, (Drug Develop Ind Pharm 15 (1989) 1523), “Liposome Dermatics” (Springer Verlag 1992) and Hayashi (Gene Therapy 3 (1996) 878).
Optionally, the pharmaceutical composition may comprise two or more different antisense oligonucleotides or conjugates thereof. Optionally, the pharmaceutical composition may further comprise one or more antisense oligonucleotides or conjugates thereof targeting different exons, suitably different exons of the human dystrophin pre-mRNA. Optionally, the one or more further antisense oligonucleotides or conjugates thereof may target exons adjacent to exon 51, for example, exon 50 or exon 52 of the human dystrophin pre-mRNA. Suitably, the one or more antisense oligonucleotides or conjugates thereof targeting different exons of the human dystrophin pre-mRNA are operable, together with the antisense oligonucleotide of the invention, to restore the reading frame of dystrophin mRNA.
Optionally, the pharmaceutical composition may further comprise one or more antisense oligonucleotides or conjugates thereof targeting different genes. For example, the one or more further antisense oligonucleotides or conjugates thereof may target myostatin. Such dual targeting is described in ‘Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy’ Kemaladewi et al. BMC Med Genomics. 2011 Apr. 20; 4:36.
Optionally, the one or more further antisense oligonucleotides may be joined together and/or joined to the antisense oligonucleotide of the first aspect.
Optionally, the antisense oligonucleotide and/or conjugate may be present in the pharmaceutical composition as a physiologically tolerated salt. Suitably, physiologically tolerated salts retain the desired biological activity of the antisense oligonucleotide and/or conjugate thereof and do not impart undesired toxicological effects. For antisense oligonucleotides, suitable examples of pharmaceutically acceptable salts include (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.
Optionally, the pharmaceutical composition may comprise, in addition to at least one antisense oligonucleotide and/or conjugate, one or more different therapeutically active ingredients. The one or more therapeutically active ingredients may be selected from, for example: corticosteroids, utrophin-upregulators, TGF-beta inhibitors, and myostatin inhibitors.
Suitably, in addition to the active ingredients and excipients, a pharmaceutical composition may also comprise additives, such as fillers, extenders, disintegrants, binders, lubricants, wetting agents, stabilizing agents, emulsifiers, preservatives, sweeteners, dyes, flavorings or aromatizing agents, thickeners, diluents or buffering substances, and, in addition, solvents and/or solubilizing agents and/or agents for achieving a slow release effect, and also salts for altering the osmotic pressure, coating agents and/or antioxidants. Suitable additives may include Tris-HCl, acetate, phosphate, Tween 80, Polysorbate 80, ascorbic acid, sodium metabisulfite, Thimersol, benzyl alcohol, lactose, mannitol, or the like.
Administration
The present invention relates to a therapeutic antisense oligonucleotide and to a pharmaceutical composition comprising the therapeutic antisense oligonucleotide which are for administration to a subject.
Suitably, the antisense oligonucleotide and/or pharmaceutical composition may be for topical, enteral or parenteral administration.
Suitably, the antisense oligonucleotide and/or pharmaceutical composition may be for administration orally, transdermally, intravenously, intrathecally, intramuscularly, subcutaneously, nasally, transmucosally or the like.
In one embodiment, the antisense oligonucleotide and/or pharmaceutical composition is for intramuscular administration.
In one embodiment, the antisense oligonucleotide and/or pharmaceutical composition is for intramuscular administration by injection.
An ‘effective amount’ or ‘therapeutically effective amount’ refers to an amount of the antisense oligonucleotide, administered to a subject, either as a single dose or as part of a Page 19 Header series of doses, which is effective to produce a desired physiological response or therapeutic effect in the subject.
Suitably, the desired physiological response includes increased expression of a relatively functional or biologically active form of the dystrophin protein, suitably in muscle tissues or cells that contain a defective dystrophin protein or no dystrophin.
Suitably, the desired therapeutic effects include improvements in the symptoms or pathology of a muscular disorder, reducing the progression of symptoms or pathology of a muscular disorder, and slowing the onset of symptoms or pathology of a muscular disorder. Examples of such symptoms include fatigue, mental retardation, muscle weakness, difficulty with motor skills (e.g., running, hopping, jumping), frequent falls, and difficulty walking.
Suitably, the antisense oligonucleotide or conjugate thereof are administered at a dose in the range from about 0.0001 to about 100 mg per kilogram of body weight per day.
Suitably, the antisense oligonucleotide or conjugate thereof are administered daily, once every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 days, once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 weeks, or once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months.
Suitably, the dose and frequency of administration may be decided by a physician, as needed, to maintain the desired expression of a functional dystrophin protein.
Suitably, the antisense oligonucleotide or conjugate thereof may be administered as two, three, four, five, six or more sub-doses separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
Subject
The present invention also relates to treatment of a muscular disorder by administering a therapeutically effective amount of the antisense oligonucleotide or conjugate thereof to a subject in need thereof.
Suitably the subject has a muscular disorder, as defined above.
Suitably, the subject is mammalian. Suitably the subject is human.
Suitably the subject may be male or female. However, suitably the subject is male.
Suitably, the subject is any age. However, suitably the subject is between the ages of 1 month old to 50 years old, suitably between the ages of 1 years old and 30 years old, suitably between the ages of 2 years old to 27 years old, suitably between the ages of 4 years old to 25 years old
Increased Exon Skipping and Dystrophin Expression
The present invention relates to a therapeutic antisense oligonucleotide for use in the treatment of muscular disorder by inducing exon skipping in the human dystrophin pre-mRNA to restore functional dystrophin protein expression.
Suitably, a ‘functional’ dystrophin protein refers to a dystrophin protein having sufficient biological activity to reduce the progressive degradation of muscle tissue that is otherwise characteristic of muscular dystrophy when compared to the defective form of dystrophin protein that is present in subjects with a muscular disorder such as DMD.
Suitably, a functional dystrophin protein may have about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of the in vitro or in vivo biological activity of wild-type dystrophin. Suitably, a functional dystrophin protein has at least 10% to 20% of the in vitro or in vivo biological activity of wild-type dystrophin.
Suitably, the activity of dystrophin in muscle cultures in vitro can be measured according to myotube size, myofibril organization, contractile activity, and spontaneous clustering of acetylcholine receptors (see, e.g., Brown et al., Journal of Cell Science. 112:209-216, 1999).
Animal models are also valuable resources for studying the pathogenesis of disease, and provide a means to test dystrophin-related activity. Two of the most widely used animal models for DMD research are the mdx mouse and the golden retriever muscular dystrophy (GRMD) dog, both of which are dystrophin negative (see, e.g., Collins & Morgan, Int J Exp Pathol 84: 165-172, 2003). These and other animal models can be used to measure the functional activity of various dystrophin proteins.
Suitably, ‘exon skipping’ refers to the process by which an entire exon, or a portion thereof, is removed from a given pre-processed RNA (pre-mRNA), and is thereby excluded from being present in the mature RNA that is translated into a protein.
Suitably, the portion of the protein that is otherwise encoded by the skipped exon is not present in the expressed form of the protein.
Suitably therefore, exon skipping creates a truncated, though still functional, form of the protein as defined above.
Suitably, the exon being skipped is an exon from the human dystrophin gene, which may contain a mutation or other alteration in its sequence that otherwise causes aberrant splicing.
Suitably, the exon being skipped is exon 51 of the dystrophin gene.
Suitably, the antisense oligonucleotide is operable to induce exon skipping in dystrophin pre-mRNA.
Suitably, the antisense oligonucleotide is operable to induce exon skipping of exon 51 in dystrophin pre-mRNA.
Suitably, the antisense oligonucleotide is operable to increase expression of a functional form of a dystrophin protein in muscle tissue, and is operable to increase muscle function in muscle tissue.
Suitably, the antisense oligonucleotide is operable to increase muscle function by at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% compared to muscle function in subjects with a muscular disorder such as DMD that have not received the antisense oligonucleotide.
Suitably, the antisense oligonucleotide is operable to increase the percentage of muscle fibres that express a functional dystrophin protein in about at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of muscle fibres compared to subjects with a muscular disorder such as DMD that have not received the antisense oligonucleotide.
Suitably, the antisense oligonucleotide is operable to induce expression of a functional form of a dystrophin protein to a level of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 25, 40, 45, or 50% of the expression of dystrophin protein in wild type cells and/or subjects. Suitably, the antisense oligonucleotide is operable to induce expression of a functional form of a dystrophin protein to a level of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20% of the expression of dystrophin protein in wild type cells and/or subjects.
Suitably, the antisense oligonucleotide is operable to induce expression of a functional form of a dystrophin protein to a level of at least 10, 15, or 20% of the expression of dystrophin protein in wild type cells and/or subjects.
Suitably, the antisense oligonucleotide is operable to induce exon 51 skipping in the dystrophin pre-mRNA to a level of at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%.
Suitably, the antisense oligonucleotide is operable to induce exon 51 skipping in the dystrophin pre-mRNA to a level of at least 60%, 70%, 80%, 90%, or 100%.
Suitably, the antisense oligonucleotide is operable to induce exon 51 skipping in the dystrophin pre-mRNA to a level of between 60% to 80%.
An ‘increased’ or ‘enhanced’ amount may include an increase that is 1.1, 1.2, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50 or more times the amount produced when no antisense oligonucleotide compound (the absence of an agent) or a control compound is administered under the same circumstances.
Suitably, an ‘increased’ or ‘enhanced’ amount is a statistically significant amount.
Certain embodiments of the present invention will now be described with reference to the following figures and tables in which:
muscle cells with exon 52 deletion (KM571) are shown as represented by RT-PCR. (E-H) indicate the results in immortalized DMD cells with exons 48-50 deletion. The data are shown from 3 independent experiments.
Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of them mean “including but not limited to”, and they are not intended to (and do not) exclude other moieties, additives, components, integers or steps. Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or 27 process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive.
The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed. The reader's attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.
Materials and Methods
1.1 Design and in Silico Screening of AOs.
413 30-mer and 25-mer AOs targeting exon 51 were designed and analysed using the AO predictive algorithm we recently developed (see Table 3). Table 3 shows in the columns from left to right; the exon number, the distance from acceptor splice site, the AO sequence (5′ to 3′), the predicted skipping %, and the ranking within the screen. The left hand AOs are 30mers and the right hand AOs are 25-mers. Based on predicted exon skipping efficiencies, 8 AOs spaced at least 4 bases apart were selected for in vitro screening (Table 2). Target sequence specificities of selected AOs, eteplirsen, and drisapersen were analysed using The University of California, Santa Cruz Genome Browser (http://genome.ucsc.edu/index.html), confirming that the AO sequences theoretically do not bind any non-target RNA sequences with 100% identity.
1.2 Antisense Morpholinos.
All antisense sequences, including analog AOs of eteplirsen and drisapersen, were synthesized with the morpholino chemistry by Gene Tools (Philomath, Oreg.).
1.3 Cells.
Immortalized human skeletal muscle cells derived from three healthy subjects (IDs 8220, CHQ, and KM155) and two DMD patients harbouring deletion mutations of exon 52 (ID KM571) and exons 48-50 (ID 6594) in the DMD gene, respectively, were generated by transduction with human telomerase-expressing and cyclin-dependent kinase 4-expressing vectors in the Institute of Myology human cell immortalization platform, as previously described.33 The three immortalized healthy muscle cell lines were characterized and the clonal line 8220, which showed the highest dystrophin expression was selected as a positive control to prevent overestimation of rescued dystrophin expression in immortalized DMD cells. Primary skeletal muscle cells derived from DMD patients with deletion mutations of ex45-50 (ID 4546) and ex49-50 (ID 4555) and a healthy subject were prepared by the BioBank of Skeletal Muscle, Nerve Tissue, DNA and cell lines.
1.4 AO Transfection.
To mimic as closely as possible the in vivo effects of AO-mediated exon skipping therapy, mature, differentiated myotubes expressing sufficient levels of DMD mRNA were used for in vitro screening. Cells were cultured in proliferation conditions with growth medium (GM): DMEM/F12 with skeletal muscle supplement mix (Promocell, Heidelberg, Germany), 20% fetal bovine serum (Life Technologies, Waltham, Mass.), and antibiotics (50 units penicillin and 50 μg/ml streptomycin, Life Technologies, Waltham, Mass.). Immortalized and primary DMD skeletal muscle cells were seeded at 1.7×104/cm2 and 2.2×104/cm2, respectively, in collagen type I-coated 12 or 24-well culture plates. Two days after seeding, at approximately 80-90% confluence, GM was replaced with differentiation medium (DM): DMEM/F12 with 2% horse serum (GE Healthcare, Chicago, Ill.), lx ITS solution (Sigma, St. Louis, Mo.), and antibiotics. After three days in DM, cells were transfected with AO at 1, 3, 5 or 10 μM containing 6 μM of Endo-porter transfection reagent (Gene Tools, Philomath, Oreg.) (concentrated AOs at 1 mM were incubated at 65° C. for 10 min just before diluting with DM). Two days following AO transfection, AO-containing DM was replaced with regular DM. Cells were harvested at day 2, 5, or 11 after AO transfection (day 5, 8 or 14 following differentiation).
1.5 Mice.
Animal studies were approved by the Animal Care and Use Committee at the University of Alberta, Children's National Medical Center, and National Center of Neurology and Page 27 Header Psychiatry (NCNP). Male and female Dmd exon 52-deficient mdx5242 and wild-type mice (Jackson Laboratory, Bar Harbor, Me.) with a C57BL/6J background were prepared at age 4-8 weeks. Dmd mutation in affected mice was confirmed by genotyping with PCR. A transgenic mouse model harboring the human DMD gene and lacking the mouse Dmd gene (hDMD/Dmd-null mouse) was generated by cross-breeding male hDMD mice (Jackson Laboratory, Bar Harbor, Me.) with female Dmd-null mice.
1.6 Intramuscular Injection.
Mouse version morpholinos of Ac0, Ac48, eteplirsen or drisapersen at 5 or 20 μg in 40 μL saline were intramuscularly injected into tibialis anterior (TA) muscle under inhalation anesthesia with isoflurane as previously described.43 Fifty-μg of Ac0 morpholino and analog eteplirsen in 30 μL saline was injected into TA muscles of hDMD/Dmd-null mice. All muscle samples were harvested 2 weeks after intramuscular injection.
1.7 Exon Skipping Analysis by RT-PCR.
Total RNA was extracted with Trizol (Invitrogen, Waltham, Mass.) as previously described. RT-PCR to detect dystrophin mRNA was performed with the SuperScript III One-Step RT-PCR System (Invitrogen, Waltham, Mass.) and 0.2 μM of forward and reverse primers (see Table 1) for 200 ng and 320 ng of total RNA in immortalized and primary skeletal muscle cells, respectively. Primers were designed using Primer3Plus software and their specificity was confirmed in healthy human skeletal muscle cells (line 8220). The RT-PCR conditions were as follows: 50° C. for 5 minutes; 94° C. for 2 minutes; 35 cycles at 94° C. for 15 seconds, 60° C. for 30 seconds, and 68° C. for 35 seconds; and 68° C. for 5 minutes. PCR products were separated on a 1.5% agarose gel and visualized by SYBR Safe DNA Gel Stain (Invitrogen, Waltham, Mass.). Using ImageJ software (NIH) or the MCE-202 MultiNA system (Shimadzu, Kyoto, Japan), the efficiency of exon 51 skipping was calculated using the following formula:
Unknown top bands above the native band, possibly coming from unexpected splicing events, were excluded from quantification of skipping efficiency. The sequences of the PCR products were confirmed with Big Dye Terminator v3.1 (Applied Biosystems, Waltham, Mass.). GAPDH or 18S ribosomal RNA was used as an internal control.
1.8 Western Blotting
Cells were harvested with RIPA buffer (Thermo Scientific, Waltham, Mass.) containing cOmplete, Mini, EDTA-free protease inhibitor cocktail (Roche, Basel, Switzerland), and then homogenized by passing through a 21-gauge needle 10 times. The supernatants as loading samples were prepared by centrifugation at 14,000 g for 15 min at 4° C. Protein from muscle tissues were prepared as previously described. Protein concentrations were adjusted using the Bradford assay with supernatants diluted 100 times with distilled water. Proteins in a sample buffer containing 10% SDS, 70 mM Tris-HCl, pH 6.8, 5 mM EDTA, 20% glycerol, 0.004% bromophenol blue and 5% 2-mercaptoethanol were heated at 70° C. for 10 min. Western blotting was then done as previously described. 32,43,44 Twelve-μg and thirty-μg from cells and tissues, respectively, were used for sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Blots were incubated with a rabbit polyclonal antibody against dystrophin C-terminal (1:2500, ab15278, Abcam, Cambridge, United Kingdom) in the blocking solution or DYS1 antibody against dystrophin rod domain (1:400, Leica Biosystems, Buffalo Grove, Ill.) for 1 hour at room temperature. The primary antibody was reacted with HRP-conjugated anti-rabbit or mouse IgG H+L antibody (1:10,000, Bio-Rad, Hercules, Calif.). Expression levels of dystrophin protein induced by AOs were quantified using calibration curves (R2=0.93-0.99) from dystrophin protein of healthy 8220 skeletal muscle cells diluted with protein from non-treated DMD cells, or wild-type mouse using ImageJ (NIH). Alpha-tubulin was detected on the same membrane as a loading control. Myosin heavy chain (MyHC) on post-transferred gels was stained with Coomassie Brilliant Blue (Bio-Rad, Hercules, Calif.) as a loading control/differentiation marker.
1.9 Immunocytochemistry.
Cells were fixed with 4% paraformaldehyde for 5 min at room temperature. After washing with PBS containing 0.01% Triton X-100, cells were blocked with 10% goat serum (Life Technologies, Waltham, Mass.) in PBS with 0.05% Triton X-100 for 20 min and then incubated with anti-dystrophin C-terminal (ab15278) or rod-domain (DYS1) antibody at 1:50 dilution in blocking solution overnight at 4° C. Dystrophin signals were detected with Alexa 488- or 594-conjugated secondary antibody (1:500). Desmin (1:80, Abcam, Cambridge, United Kingdom) and MyHC-fast type (1:30, Leica Biosystems, Buffalo Grove, Ill.) were detected to confirm myogenic differentiation of cells. Cells were stored in SlowFade Gold Antifade Mountant with DAPI (Invitrogen, Waltham, Mass.) at 4° C. until analysed.
1.10 Immunohistochemistry.
Dystrophin-positive muscle fibers on cryosections from TA muscles of non-treated and treated mdx52 mice were detected with the ab15278 antibody as previously described. Signal intensity of dystrophin in the treated mice was compared with that in wild-type using neutral density filters (Eclipse TE 2000-U, Nikon, Tokyo, Japan).
1.11 Statistical Analysis.
For determining the significance of efficiencies in exon skipping and dystrophin protein rescue, data sets were prepared from at least three independent experiments in immortalized cells, triplicate wells in primary cells, and 3-7 mice. The statistical analysis between AO-treated groups was performed by one-way ANOVA followed by a post hoc Tukey-Kramer multiple comparison test. Simple linear regression analysis was performed for dose-responsiveness to AOs. Statistical significance was set at p<0.05 for all analyses.
2. Results
2.1 in Silico Screening of AOs for Exon 51 Skipping.
We designed total 413 AOs: 204 and 209 AOs with 30-mer and 25-mer lengths, respectively, which cover all possible target sites in DMD exon 51 (see Table 3). Our exon skipping efficiency algorithm (In Silico Screening Based on Predictive Algorithms as a Design Tool for Exon Skipping Oligonucleotides in Duchenne Muscular Dystrophy’ Echigoya et al. PLOS ONE March 2015) predicted that the highest efficiency for exon 51 skipping was 80.5% for 30-mer AOs, and 41.2% for 25-mer AOs in the initial 5′ site of exon 51. In silico screening indicated a very low exon skipping efficiency for the 30-base region targeted by eteplirsen (23.7%), which was ranked 92nd in all 413 AO candidates tested. It is noted that the drisapersen target site is completely encompassed by that of the 30-mer eteplirsen.
2.2 Characterization of Immortalized Clonal Healthy and DMD Skeletal Muscle Cell Lines.
Significant issues in preclinical testing with primary DMD muscle cells include low purity of muscle cells and insufficient amounts of mutant dystrophin mRNA, which present problems when trying to test AO efficacy. To overcome these hurdles, we generated immortalized clonal skeletal muscle cells from 3 healthy subjects and 2 DMD patients with exon 52 (ex52) and ex48-50 deletion (del.) mutations (IDs KM571 and 6594, respectively). All immortalized skeletal muscle cell lines tested expressed easily detectable dystrophin mRNA from day 3 Page 31 Header after induction of differentiation. To avoid overestimation of dystrophin protein levels induced by AOs in DMD cells, we selected a cell line (ID 8220) with the highest level of dystrophin protein among three immortalized healthy skeletal muscle cell lines as determined by Western blotting to serve as a positive control. Dystrophin protein expression in the 8220 cell line was also confirmed by immunocytochemistry.
2.3 In Vitro Screening of Exon 51 Skipping AOs.
Based on the in silico screening results, we selected eight 30-mer AOs, including both high-ranking and low-ranking sequences, spaced at least 4 bases apart from each other for in vitro screening (Table 2). In the present study, all tested AOs, including eteplirsen and drisapersen sequences, were synthesized using the morpholino chemistry that has been demonstrated to be well-tolerated in patients enrolled in clinical trials. Here, we termed control morpholino oligonucleotides having the same sequences as eteplirsen and drisapersen (produced by Gene Tools) as “analog eteplirsen” and “analog drisapersen”. In RT-PCR, 5 of our morpholino AOs (Ac0, Ac5, Ac26, Ac30 and Ac48) at 10 μM showed significantly higher skipping efficiency compared to analog eteplirsen and drisapersen in immortalized DMD skeletal muscle cells harboring ex52 del. (
2.4 Time-Course Analysis with Ac0, Ac48, and Analog AOs of Eteplirsen and Drisapersen.
The persistent effects of Ac0, Ac48, and analogs of eteplirsen and drisapersen at 5 μM were examined in ex52 del. KM571 cells. The superiority of the oligonucleotides Ac0 and Ac48 of the present invention, with respect to exon skipping efficiency and dystrophin protein rescue, was observed at days 2 and 11 post-transfection compared to analog AOs of eteplirsen and drisapersen (
2.5 Dose-Dependent Effects of Ac0, Ac48, and Analog Eteplirsen and Drisapersen.
RT-PCR showed that Ac0 at the highest concentration of 10 μM induced up to 74% and 64% exon 51 skipping in DMD KM571 (ex52 del.) and 6594 cells (ex48-50 del.), respectively, which were significantly higher than analogs of eteplirsen and drisapersen (
2.6 Immunocytochemical Assessment of Dystrophin Protein Rescue.
Immunocytochemistry revealed that Ac0 and Ac48 at 10 μM yielded more dystrophin-positive myotubes and displayed stronger signal intensity in DMD skeletal muscle cell lines harboring ex52 and ex48-50 del. mutations compared to analog eteplirsen (
2.7 Length Optimization of Ac0 Morpholino.
In silico and in vitro screening revealed that the initial 5′ region of exon 51 between 0 and +89 is an important region for influencing exon 51 skipping. To optimize the sequence length of Ac0 targeting this region, we compared the skipping efficiencies of Ac0 morpholinos of different lengths (25- to 30-mer), in which nucleotides at the 5′ site were systematically removed one at a time (see Table 2). In vitro testing in immortalized DMD muscle cells treated with 1 μM of these AOs showed that 25-30-mer Ac0 morpholinos produced efficient exon skipping (>20%) (
2.8 Effect of Ac0, Ac48, and Analog Eteplirsen and Drisapersen on Primary DMD Patient-Derived Skeletal Muscle Cells.
We also tested the AOs in primary DMD skeletal muscle cells with exons 45-50 (ID 4546) or exons 49-50 del. mutations (ID 4555) to validate if the superior efficacy of 30-mer Ac0 is consistent for other muscle cell types and deletion mutation patterns. RT-PCR showed that Ac0 achieved significantly higher exon skipping efficiency in both primary DMD muscle cells compared to analog eteplirsen, or analog drisapersen (
2.10 In Vivo Efficacy of Ac0 Morpholino and Analog Eteplirsen in hDMD/Dmd-Null Mice.
A major hurdle in the development of exon skipping therapy is that human-specific AOs cannot always be tested in an appropriate animal model. This limits the evaluation of in vivo effects of AOs designed for patients. Here, we developed a new mouse model that has the full-length human DMD gene but lacks the entire mouse Dmd gene (hDMD/Dmd-null) to test the in vivo efficacy of human AOs. This mouse model was employed to avoid the cross-reaction between human sequences and mouse sequences (note that conventional mdx mice still have the mouse dystrophin mRNA, which can cross-react with human-targeting AOs), and obtained by cross-breeding between hDMD mice34 and Dmd-null mice35. Ac0, Ac48, analog eteplirsen or analog drisapersen was injected into TA muscles of these mice, and the effectiveness of in vivo exon 51 skipping was analysed 2 weeks after the injection. The result showed significantly greater exon skipping efficiency in mice treated with Ac0 compared to analog eteplirsen (
| Number | Date | Country | Kind |
|---|---|---|---|
| 1711809 | Jul 2017 | GB | national |
This application is a continuation of U.S. patent application Ser. No. 16/632,827, filed on Jan. 21, 2020, which is a U.S. National Phase Entry of International Application No. PCT/CA2018/050881, filed on Jul. 20, 2018, which claims the benefit of foreign priority to Application No. GB 1711809.2, filed Jul. 21, 2017, each of which is incorporated herein by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4458066 | Caruthers et al. | Jul 1984 | A |
| 4694778 | Learn et al. | Sep 1987 | A |
| 5034506 | Summerton et al. | Jul 1991 | A |
| 5142047 | Summerton et al. | Aug 1992 | A |
| 5166315 | Summerton et al. | Nov 1992 | A |
| 5185444 | Summerton et al. | Feb 1993 | A |
| 5217866 | Summerton et al. | Jun 1993 | A |
| 5334711 | Sproat et al. | Aug 1994 | A |
| 5506337 | Summerton et al. | Apr 1996 | A |
| 5521063 | Summerton et al. | May 1996 | A |
| 5627053 | Usman et al. | May 1997 | A |
| 5698685 | Summerton et al. | Dec 1997 | A |
| 5716824 | Beigelman et al. | Feb 1998 | A |
| 5736557 | Hofheinz et al. | Apr 1998 | A |
| 5889136 | Scaringe et al. | Mar 1999 | A |
| 6008400 | Scaringe et al. | Dec 1999 | A |
| 6111086 | Scaringe | Aug 2000 | A |
| 6194551 | Idusogie et al. | Feb 2001 | B1 |
| 6528624 | Idusogie et al. | Mar 2003 | B1 |
| 6538124 | Idusogie et al. | Mar 2003 | B1 |
| 6821783 | Comely et al. | Nov 2004 | B1 |
| 6884869 | Senter et al. | Apr 2005 | B2 |
| 7364731 | Idusogie et al. | Apr 2008 | B2 |
| 7452987 | Giese et al. | Nov 2008 | B2 |
| 7498258 | Hiatt | Mar 2009 | B2 |
| 7498298 | Doronina et al. | Mar 2009 | B2 |
| 7736647 | Boumsell et al. | Jun 2010 | B2 |
| 7791195 | Kim | Sep 2010 | B2 |
| 7833992 | Vargeese et al. | Nov 2010 | B2 |
| 7850975 | Mullis | Dec 2010 | B2 |
| 7893245 | Giese et al. | Feb 2011 | B2 |
| 7923547 | Mcswiggen et al. | Apr 2011 | B2 |
| 7943762 | Weller et al. | May 2011 | B2 |
| 8084582 | Dahiyat et al. | Dec 2011 | B2 |
| 8084598 | Bentwich | Dec 2011 | B1 |
| 8090542 | Khvorova et al. | Jan 2012 | B2 |
| 8202979 | Mcswiggen et al. | Jun 2012 | B2 |
| 8248352 | Kim et al. | Aug 2012 | B2 |
| 8273866 | Mcswiggen et al. | Sep 2012 | B2 |
| 8288352 | Doronina et al. | Oct 2012 | B2 |
| 8324370 | Giese et al. | Dec 2012 | B2 |
| 8324371 | Popplewell et al. | Dec 2012 | B2 |
| 8361979 | Aartsma-Rus et al. | Jan 2013 | B2 |
| 8461325 | Popplewell et al. | Jun 2013 | B2 |
| 8501703 | Bennett et al. | Aug 2013 | B2 |
| 8501930 | Rozema et al. | Aug 2013 | B2 |
| 8591910 | Mullis | Nov 2013 | B2 |
| 8604184 | Mullis et al. | Dec 2013 | B2 |
| 8609105 | Senter et al. | Dec 2013 | B2 |
| 8618277 | Beigelman et al. | Dec 2013 | B2 |
| 8637483 | Wilton | Jan 2014 | B2 |
| 8648185 | Mcswigen et al. | Feb 2014 | B2 |
| 8697688 | Howard et al. | Apr 2014 | B2 |
| 8835402 | Kole et al. | Sep 2014 | B2 |
| 8865883 | Sazani | Oct 2014 | B2 |
| 8895722 | Iversen et al. | Nov 2014 | B2 |
| 8933215 | Giese et al. | Jan 2015 | B2 |
| 8936910 | Mitsch et al. | Jan 2015 | B2 |
| 8969526 | Baehner et al. | Mar 2015 | B2 |
| 9078911 | Lu | Jul 2015 | B2 |
| 9089614 | Lin et al. | Jul 2015 | B2 |
| 9096877 | Johnson et al. | Aug 2015 | B2 |
| 9139828 | Platenburg et al. | Sep 2015 | B2 |
| 9175286 | Wilton et al. | Nov 2015 | B2 |
| 9181551 | Mcswiggen et al. | Nov 2015 | B2 |
| 9222092 | Giese et al. | Dec 2015 | B2 |
| 9228187 | Wilton et al. | Jan 2016 | B2 |
| 9243251 | Popplewell et al. | Jan 2016 | B2 |
| 9243252 | Popplewell et al. | Jan 2016 | B2 |
| 9249416 | Wilton et al. | Feb 2016 | B2 |
| 9260471 | Cancilla et al. | Feb 2016 | B2 |
| 9416361 | Iversen et al. | Aug 2016 | B2 |
| 9434948 | Sazani et al. | Sep 2016 | B2 |
| 9441229 | Wilton et al. | Sep 2016 | B2 |
| 9447415 | Wilton et al. | Sep 2016 | B2 |
| 9447417 | Sazani et al. | Sep 2016 | B2 |
| 9481905 | Chen et al. | Nov 2016 | B2 |
| 9499818 | Van Deutekom | Nov 2016 | B2 |
| 9528109 | De Kimpe et al. | Dec 2016 | B2 |
| 9598496 | Kurosawa et al. | Mar 2017 | B2 |
| 9605019 | Verdine et al. | Mar 2017 | B2 |
| 9657294 | Beigelman et al. | May 2017 | B2 |
| 9695211 | Wada et al. | Jul 2017 | B2 |
| 9695423 | Giese et al. | Jul 2017 | B2 |
| 9732344 | Beigelman et al. | Aug 2017 | B2 |
| 9765338 | Bennett et al. | Sep 2017 | B2 |
| 9771588 | Mcswiggen et al. | Sep 2017 | B2 |
| 9796974 | Rajeev et al. | Oct 2017 | B2 |
| 9890379 | De Kimpe et al. | Feb 2018 | B2 |
| 9926557 | De Kimpe et al. | Mar 2018 | B2 |
| 9982257 | Butler et al. | May 2018 | B2 |
| 10000754 | Beigelman et al. | Jun 2018 | B2 |
| 10704060 | Gersbach et al. | Jul 2020 | B2 |
| 11142767 | Yokota et al. | Oct 2021 | B2 |
| 11179472 | Levin et al. | Nov 2021 | B2 |
| 11311627 | Levin et al. | Apr 2022 | B1 |
| 11400163 | Levin et al. | Aug 2022 | B2 |
| 20020142980 | Thompson et al. | Oct 2002 | A1 |
| 20080311557 | Elsemore et al. | Dec 2008 | A1 |
| 20090092985 | Cardozo et al. | Apr 2009 | A1 |
| 20110081362 | Elledge et al. | Apr 2011 | A1 |
| 20110263686 | Wilton et al. | Oct 2011 | A1 |
| 20110294753 | De Kimpe et al. | Dec 2011 | A1 |
| 20110301218 | Bozzoni et al. | Dec 2011 | A1 |
| 20120065169 | Hanson et al. | Mar 2012 | A1 |
| 20120094299 | Ranum et al. | Apr 2012 | A1 |
| 20120172415 | Voit et al. | Jul 2012 | A1 |
| 20120270925 | Wilton et al. | Oct 2012 | A1 |
| 20120289457 | Hanson | Nov 2012 | A1 |
| 20130024919 | Wetter et al. | Jan 2013 | A1 |
| 20130028919 | Howard et al. | Jan 2013 | A1 |
| 20130172238 | Mitsch et al. | Jul 2013 | A1 |
| 20130309256 | Lyon et al. | Nov 2013 | A1 |
| 20140127239 | Howard | May 2014 | A1 |
| 20140194610 | Verdine et al. | Jul 2014 | A1 |
| 20140246970 | Park et al. | Sep 2014 | A1 |
| 20140254851 | Chen | Sep 2014 | A1 |
| 20140286970 | Jeffrey et al. | Sep 2014 | A1 |
| 20140294851 | Nguyen | Oct 2014 | A1 |
| 20140296321 | Iversen | Oct 2014 | A1 |
| 20140315862 | Kaye | Oct 2014 | A1 |
| 20150037360 | Smith | Feb 2015 | A1 |
| 20150105539 | Miao et al. | Apr 2015 | A1 |
| 20150105540 | Miao et al. | Apr 2015 | A1 |
| 20150110791 | Zhang et al. | Apr 2015 | A1 |
| 20150211006 | Butler et al. | Jul 2015 | A1 |
| 20150361428 | Bestwick | Dec 2015 | A1 |
| 20160002637 | Sazani et al. | Jan 2016 | A1 |
| 20160053262 | Platenburg et al. | Feb 2016 | A1 |
| 20160102135 | Escobar-Cabrera | Apr 2016 | A1 |
| 20160193355 | Qin et al. | Jul 2016 | A1 |
| 20160201089 | Gersbach et al. | Jul 2016 | A1 |
| 20160237426 | Hanson | Aug 2016 | A1 |
| 20160298111 | Bestwick et al. | Oct 2016 | A1 |
| 20160304864 | De Kimpe et al. | Oct 2016 | A1 |
| 20160304877 | Swayze et al. | Oct 2016 | A1 |
| 20160367687 | Manoharan et al. | Dec 2016 | A1 |
| 20170067048 | Wakayama et al. | Mar 2017 | A1 |
| 20170107512 | De Kimpe et al. | Apr 2017 | A1 |
| 20170204410 | Watanabe et al. | Jul 2017 | A1 |
| 20170204414 | Van Deutekom et al. | Jul 2017 | A1 |
| 20170281795 | Geall et al. | Oct 2017 | A1 |
| 20170342416 | Mcswiggen et al. | Nov 2017 | A1 |
| 20180016574 | Bestwick et al. | Jan 2018 | A1 |
| 20180044675 | Watanabe et al. | Feb 2018 | A1 |
| 20180112214 | De Kimpe et al. | Apr 2018 | A1 |
| 20180127758 | Bennett | May 2018 | A1 |
| 20180163209 | Bennett et al. | Jun 2018 | A1 |
| 20180305689 | Sætrom et al. | Oct 2018 | A1 |
| 20180369400 | Levin et al. | Dec 2018 | A1 |
| 20190240346 | Sugo et al. | Aug 2019 | A1 |
| 20200282074 | Levin et al. | Sep 2020 | A1 |
| 20220096647 | Geall et al. | Mar 2022 | A1 |
| 20220235354 | Darimont et al. | Jul 2022 | A1 |
| 20220313833 | Levin et al. | Oct 2022 | A1 |
| Number | Date | Country |
|---|---|---|
| 2013204438 | May 2013 | AU |
| 102625840 | Aug 2012 | CN |
| 103003430 | Mar 2013 | CN |
| 106459955 | Feb 2017 | CN |
| 0336675 | Oct 1989 | EP |
| 0334656 | Mar 1994 | EP |
| 1579015 | Sep 2005 | EP |
| 1068241 | Oct 2007 | EP |
| 2119783 | Nov 2009 | EP |
| 2049664 | Sep 2011 | EP |
| 2386636 | Nov 2011 | EP |
| 2278004 | Oct 2012 | EP |
| 2602322 | Jun 2013 | EP |
| 2796425 | Oct 2014 | EP |
| 2344637 | Dec 2014 | EP |
| 1423406 | Nov 2015 | EP |
| 3031920 | Jun 2016 | EP |
| 2421971 | Jul 2016 | EP |
| 2287306 | Oct 2016 | EP |
| 3118311 | Jan 2017 | EP |
| 3030658 | Mar 2017 | EP |
| 2287305 | Nov 2017 | EP |
| 2486141 | Jan 2018 | EP |
| 2902406 | Jan 2018 | EP |
| 2595664 | Oct 2018 | EP |
| WO-9104753 | Apr 1991 | WO |
| WO-9207065 | Apr 1992 | WO |
| WO-9315187 | Aug 1993 | WO |
| WO-9726270 | Jul 1997 | WO |
| WO-9734631 | Sep 1997 | WO |
| WO-9813526 | Apr 1998 | WO |
| WO-0149698 | Jul 2001 | WO |
| WO-03071872 | Sep 2003 | WO |
| WO-2004009851 | Jan 2004 | WO |
| WO-2004083446 | Sep 2004 | WO |
| WO-2006000057 | Jan 2006 | WO |
| WO-2006021724 | Mar 2006 | WO |
| WO-2006112705 | Oct 2006 | WO |
| WO-2008036127 | Mar 2008 | WO |
| WO-2009005793 | Jan 2009 | WO |
| WO-2009026933 | Mar 2009 | WO |
| WO-2009054725 | Apr 2009 | WO |
| WO-2009099942 | Aug 2009 | WO |
| WO-2009099991 | Aug 2009 | WO |
| WO-2009144481 | Dec 2009 | WO |
| WO-2009147368 | Dec 2009 | WO |
| WO-2010048586 | Apr 2010 | WO |
| WO-2010050801 | May 2010 | WO |
| WO-2010050802 | May 2010 | WO |
| WO-2011057350 | May 2011 | WO |
| WO-2011078797 | Jun 2011 | WO |
| WO-2011150408 | Dec 2011 | WO |
| WO-2012109296 | Aug 2012 | WO |
| WO-2012138487 | Oct 2012 | WO |
| WO-2013030569 | Mar 2013 | WO |
| WO-2013112053 | Aug 2013 | WO |
| WO-2013166155 | Nov 2013 | WO |
| WO-2014007620 | Jan 2014 | WO |
| WO-2014080251 | May 2014 | WO |
| WO-2014140277 | Sep 2014 | WO |
| WO-2014140317 | Sep 2014 | WO |
| WO-2014145090 | Sep 2014 | WO |
| WO-2014177042 | Nov 2014 | WO |
| WO-2014197748 | Dec 2014 | WO |
| WO-2014197854 | Dec 2014 | WO |
| WO-2015021457 | Feb 2015 | WO |
| WO-2015038426 | Mar 2015 | WO |
| WO-2015048792 | Apr 2015 | WO |
| WO-2015057699 | Apr 2015 | WO |
| WO-2015069587 | May 2015 | WO |
| WO-2015075747 | May 2015 | WO |
| WO-2015107425 | Jul 2015 | WO |
| WO-2016187425 | Nov 2016 | WO |
| WO-2016207240 | Dec 2016 | WO |
| WO-2017059131 | Apr 2017 | WO |
| WO-2017109494 | Jun 2017 | WO |
| WO-2017148879 | Sep 2017 | WO |
| WO-2017173408 | Oct 2017 | WO |
| WO-2017192679 | Nov 2017 | WO |
| WO-2017221883 | Dec 2017 | WO |
| WO-2018002812 | Jan 2018 | WO |
| WO-2018118599 | Jun 2018 | WO |
| WO-2018129384 | Jul 2018 | WO |
| WO-2019014772 | Jan 2019 | WO |
| WO-2019060775 | Mar 2019 | WO |
| WO-2020132584 | Jun 2020 | WO |
| WO-2020219820 | Oct 2020 | WO |
| WO-2021003573 | Jan 2021 | WO |
| Entry |
|---|
| El-Sayed et al. (“Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment.” The AAPS journal 11.1 (2009): 13-22). |
| Aartsma-Rus et al. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther 17(3):548-53 (2009). |
| Aartsma-Rus et al. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord. 12 Suppl 1:S71-7 (2002). |
| Abramova et al. Novel oligonucleotide analogues based on morpholino nucleoside subunits-antisense technologies: new chemical possibilities. Indian Journal of Chemistry 48B:1721-1726 (2009). |
| Agarwal et al. A Pictet-Spengler ligation for protein chemical modification. PNAS 110(1):46-51 (2013). |
| Albarran et al. Efficient intracellular delivery of a pro-apoptotic peptide with a pH-responsive carrier. React Funct Polym 71:261-265 (2011). |
| Arechavala-Gomeza et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther. 18(9):798-810 (2007). |
| Axup et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. PNAS 109(40):16101-16106 (2012). |
| Baumer et al. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer. Clin Can Res 21(6):1383-1394 (2015). |
| Beduneau et al. Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab′ fragments. Biomaterials 28(33):4978-4990 (2007). |
| Beigelman et al. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J Biol Chem 270:25702-25708 (1995). |
| Bell et al. Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non-Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials. J Clin Oncol 23(31):8081-8092 (2005). |
| Bird et al. Single-chain antigen-binding proteins. Science 242:423-442 (1988). |
| Blaney et al. Traceless solid-phase organic synthesis. Chem. Rev. 102:2607-2024 (2002. |
| Brown et al. Dystrophic phenotype induced in vitro by antibody blockade of muscle alpha-dystroglycan-laminin interaction. J Cell Sci 112:209-216 (1999). |
| Bulmus et al. A new pH-responsive and glutathione-reactive, endosomal membrane-disruptive polymeric carrier for intracellular delivery of biomolecular drugs. J Controlled Release 93:105-120 (2003). |
| Burke et al. siRNA-mediated knockdown of P450 oxidoreductase in rats: a tool to reduce metabolism by CYPs and increase exposure of high clearance compounds. Pharm. Res. 31(12):3445-3460 (2014). |
| Burlina et al. Chemical engineering of RNase resistant and catalytically active hammerhead ribozymes. Bioorg Med Chem 5:1999-2010 (1997). |
| Casi et al. Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery. J Am Chem Soc 134(13):5887-5892 (2012). |
| Castaneda et al. Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation, Chem. Commun. 49:8187-8189 (2013). |
| Chen et al. Strand-specific 5′-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 14:263-274 (2008). |
| Clackson et al. Making antibody fragments using phage display libraries. Nature 352(6336):624-628 (1991). |
| Colberre-Garapin et al. A new dominant hybrid selective marker for higher eukaryotic cells. J Mol Biol 150:1-14 (1981). |
| Cole et al. The EBV-hybridoma technique and its application to human lung cancer. In, Monoclonal Antibodies and Cancer Therapy (vol. 27, UCLA Symposia on Molecular and Cellular Biology, New Series) (eds. R.A. Reisfeld and S.Sell), New York: Alan R. Liss, Inc. pp. 77-96 (1985). |
| Collins et al. Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies. Int J Exp Pathol 84:165-172 (2003). |
| Crouse et al. Expression and amplification of engineered mouse dihydrofolate reductase minigenes. Mol Cell Biol 3(2):257-266 (1983). |
| Cuellar et al. Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. Nucleic Acids Res 43(2):1189-1203 (2015). |
| Dawson et al. Modulation of Reactivity in Native Chemical Ligation through the Use of Thiol Additives. J. Am. Chem. Soc. 119:4325-4329 (1997). |
| Dawson et al. Synthesis of proteins by native chemical ligation. Science 266(5186):776-779 (1994). |
| De Angelis et al. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells. PNAS USA 99:9456-9461 (2002). |
| Debinski et al. Monovalent immunotoxin containing truncated form of Pseudomonas exotoxin as potent antitumor agent. Cancer Research 52(19):5379-5385 (1992). |
| Deleavey et al. Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol. 19(8):937-954 (2012). |
| Dietel et al. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther 22(9):417-430 (2015). |
| Dimasi et al. Development of a trispecific antibody designed to simultaneously and efficiently target three different antigens on tumor cells. Mol Pharm 12(9):3490-3501 (2015). |
| Domingo et al. Transferrin receptor as a target for antibody—drug conjugates. Methods in Enzymology 112:238-247 (1985). |
| Duncan et al. A polymer-Triton X-100 conjugate capable of pH-dependent red blood cell lysis: a model system illustrating the possibility of drug delivery within acidic intracellular compartments. J Drug Target 2:341-347 (1994). |
| Earnshaw et al. Modified oligoribonucleotides as site-specific probes of RNA structure and function. Biopolymers (Nucleic Acid Sciences) 48:39-55 (1998). |
| Echigoya et al. In Silico Screening Based on Predictive Algorithms as a Design Tool for Exon Skipping Oligonucleotides in Duchenne Muscular Dystrophy. PLoS One 10(3):e0120058 (2015). |
| El-Sayed et al. Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. The AAPS journal 11(1):13-22 (2009). |
| El-Sayed et al. Rational design of composition and activity correlations for pH-responsive and glutathione-reactive polymer therapeutics. J Control Release 104:417-427 (2005). |
| Feener et al. Alternative splicing of human dystrophin mRNA generates isoforms at the carboxy terminus. Nature 338:509-511 (Apr. 6, 1989). |
| Flanary et al. Antigen delivery with poly(propylacrylic acid) conjugation enhanced MHC-1 presentation and T-cell activation. Bioconjugate Chem. 20:241-248 (2009). |
| Gao et al. Effective Dystrophin Restoration by a Novel Muscle-Homing Peptide—Morpholino Conjugate in Dystrophin-Deficient mdx Mice. Mol Ther. 22(7):1333-1341 (2014). |
| Gaziova et al. Chemically defined polyethylene glycol siRNA conjugates with enhanced gene silencing effect. Bioorg Med Chem 22(7):2320-2326 (2014). |
| Goldspiel et al. Human gene therapy. Clin Pharm 12:488-505 (1993). |
| Griffey et al. 2′-0-aminopropyl ribonucleotides: a zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides, J. Med. Chem. 39(26):5100-5109 (1997). |
| Hackeng et al. Protein synthesis by native chemical ligation: Expanded scope by using straightforward methodology. PNAS USA 96:10068-10073 (1999). |
| Hanes et al. In vitro selection and evolution of functional proteins by using ribosome display. PNAS USA 94:4937-4942 (1997). |
| Hayash et al. Skin-specific in vivo gene and oligonucleotides transfer into fetal rats as novel model of tissue-specific overexpression of transgene or knock-out by antisense oligonucleotides. Gene Therapy 3:878-885 (1996). |
| Hejesen et al. A traceless aryl-triazene linker for DNA-directed chemistry. Org Biomol Chem 11(15):2493-2497 (2013). |
| Henry et al. pH-responsive poly(styrene-alt-maleic anhydride) alkylamide copolymers for intracellular drug delivery. Biomacromolecules 7:2407-2414 (2006). |
| Hitachi et al. Role of microRNAs in skeletal muscle hypertrophy. Front Physiol 16(4):408 (2014). |
| Hoffman et al. Restoring Dystrophin Expression in Duchenne Muscular Dystrophy Muscle: Progress in Exon Skipping and Stop Codon Read Through. Am J Pathol 179(1):12-22 (2011). |
| Hu et al. Site-specific Antibody-polymer Conjugates for siRNA Delivery. J Am Chem Soc 135(37):13885-13891 (2013). |
| Huang et al. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharma Sinica B 5(5):390-401 (2015). |
| Hudson et al. Cellular delivery of hammerhead ribozymes conjugated to a transferrin receptor antibody. Int J Pharmaceuticals 182(1):49-58 (1999). |
| Huse et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246(4935):1275-1281 (1989). |
| Huston et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. PNAS USA 85(16):5879-5883 (1988). |
| Ishikawa et al. Preparation of monomeric Fab′—horseradish peroxidase conjugate using thiol groups in the hinge and its evaluation in enzyme immunoassay and immunohistochemical staining. Ann N Y Acad Sci. 420:74-89 (1983). |
| Iversen et al. Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice. Theranostics 3(3):201-209 (2013). |
| Jancik et al. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010:150960 (13 pgs.) (2010). |
| Jearawiriyapaisarn et al. Sustained Dystrophin Expression Induced by Peptide-conjugated Morpholino Oligomers in the Muscles of mdx Mice. Mol Ther. 16(9): 1624-1629 (2008). |
| Jones et al. Poly(2-alkylacrylic acid) polymers deliver molecules to the cytosol by pH-sensitive disruption of endosomal vesicles. Biochem J 372:65-75 (2003). |
| Karpeisky et al. Highly efficient synthesis of 2′-O-amino nucleosides and their incorporation in hammerhead ribozymes. Tetrahedron Lett 39:1131-1134 (1998). |
| Kemaladewi et al. Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. BMC Med Genomics. 4:36 (2011). |
| Khormaee et al. Endosomolytic anionic polymer for the cytoplasmic delivery of siRNAs in localized in vivo applications. Adv Funct Mater 23:565-574 (2013). |
| Kim et al. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Cont Rel 116:123-129 (2006). |
| Kohler et al. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497 (1975). |
| Koizumi. ENA oligonucleotides as therapeutics. Curr Opin Mol Ther 8(2):144-149 (2006). |
| Kontermann et al. Bispecific antibodies. Drug Discov Today 20(7):838-847 (2015). |
| Kozbor et al. The production of monoclonal antibodies from human lymphocytes. Immunology Today 4:72-79 (1983). |
| Kutmeier et al. Assembly of humanized antibody genes from synthetic oligonucleotides using a single-round PCR. BioTechniques 17:242 (1994). |
| Lee et al. Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts. PLoS One 13(5):e0197084 (2018). |
| Leigh et al. The Human Plasma Proteome: History, Character, and Diagnostic Prospects. Mol Cell Proteomics 1:845-867 (2002). |
| Levin. Targeting Therapeutic Oligonucleotides. N Engl J Med 376:86-88 (2017). |
| Loakes. Survey and summary: The applications of universal DNA base analogues. Nucleic Acids Research 29:2437-2447 (2001). |
| Loh et al. A Survey of siRNA Nanoscal Delivery Patents. 11 Nanotechnology Law & Bus. (pp. 29-37) (2014). |
| Lowy et al., Isolation of transforming DNA: Cloning the hamster aprt gene. Cell 22:817-823 (1980). |
| Lyon et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nat. Biotechnol. 32(10):1059-1062 (2014). |
| Marshall et al. Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing. J Immunol Method 325(1-2):114-26 (2007). |
| Martinez et al. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110(5):563-574 (2002). |
| McEnaney et al. Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. ACS Chem Biol. 7(7):1139-1151 (2012). |
| Mei et al. FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity. J Biol Chem 290:16202-16214 (2015). |
| Miyata et al. Polymer nanotechnology for nucleic acid delivery. Drug Delivery System 31(1):44-53 (2016) (English Abstract). |
| Monaco et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2(1):90-5 (1988). |
| Morgan et al. Human gene therapy. Ann Rev Biochem 62:191-217 (1993). |
| Morrison et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. PNAS USA 81(21):6851-6855 (1984). |
| Mulligan et al. Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase. PNAS USA 78(4):2072-2076 (1981). |
| Mulligan. The basic science of gene therapy. Science 260(5110):926-932 (1993). |
| Naisbitt et al. Disposition of amodiaquine and related antimalarial agents in human neutrophils: implications for drug design. J Pharmacol Exp Ther 280:884-893 (1997). |
| Neuberger et al. Recombinant antibodies possessing novel effector functions. Nature 312(5995):604-608 (1984). |
| Normand-Sdiqui et al. Oligonucleotide delivery: Uptake of rat transferrin receptor antibody (OX / 26) conjugates into an in vitro immortalised cell line model of the blood, brain barrier. Int J Pharmaceuticals 163:63-71 (1998). |
| Obika et al. Synthesis of 2′-0,4′-C-methyleneuridine and -cytidine. Novel bicyclic nucleosides having a fixed C3′-endo sugar puckering. Tetrahedron Lett. 38(50):8735-8738 (1997). |
| O'Hare et al. Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase. PNAS USA 78:1527-1531 (1981). |
| PCT/CA2018/050881 International Search Report and Written Opinion dated Oct. 4, 2018. |
| PCT/US2018/012672 International Search Report and Written Opinion dated May 24, 2018. |
| PCT/US2018/012672 Invitation to Pay Additional Fees dated Mar. 20, 2018. |
| PCT/US2018/052289 International Search Report and Written Opinion dated Jan. 11, 2019. |
| Perrault et al. Mixed deoxyribo- and ribo-oligonucleotides with catalytic activity. Nature 344:565-568 (1990). |
| Pieken et al. Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science 253:314-317 (1991). |
| Rozema et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. PNAS USA 104(32):12982-12987 (2007). |
| Santerre et al. Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells. Gene 30(1-3):147-156 (1984). |
| Schnyder et al. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes. Biochem J 377(Pt.1):61-67 (2004). |
| Schwarz et al. Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Molecular Cell 10:537-548 (2002). |
| Sekyere et al. Examination of the distribution of the transferrin homologue, melanotransferrin (tumour antigen p97), in mouse and human. Biochimica et Biophysica Acta 1722(2):131-142 (2005). |
| Singh et al. Recent developments in oligonucleotide conjugation. Chem Soc Rev 39(6):2054-2070 (2010). |
| Skerra et al. Assembly of a functional Immunoglobulin Fv fragment in Escherichia coli. Science 240(4855):1038-1041 (1988). |
| Strop et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol 20(2):161-167 (2013). |
| Sugo et al. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. J Control release 237:1-13 (2016). |
| Summerton, et al. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. Jun. 1997;7(3):187-95. |
| Suñé-Pou et al. Targeting Splicing in the Treatment of Human Disease. Genes 8:E87 (2017). |
| Suriano et al. Beta-catenin (CTNNB1) gene amplification: a new mechanism of protein overexpression in cancer. Genes Chromosomes Cancer 42(3):238-246 (2005). |
| Szybalska et al. Genetics of human cell line. IV. DNA-mediated heritable transformation of a biochemical trait. PNAS USA 48:2026-2034 (1962). |
| Takeda et al. Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences. Nature 314(6010):452-454 (1985). |
| Talasila et al. EGFR Wild-type Amplification and Activation Promote Invasion and Development of Glioblastoma Independent of Angiogenesis. Acta Neuropathol. 125(5):683-698 (2013). |
| Tolstoshev. Gene Therapy, Concepts, Current Trials and Future Directions. Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993). |
| U.S. Appl. No. 16/128,450 Miscellaneous Communication re: Third Party Submission dated Jul. 1, 2019. |
| U.S. Appl. No. 16/128,450 Office Action dated Apr. 19, 2019. |
| U.S. Appl. No. 16/128,450 Office Action dated Apr. 30, 2020. |
| U.S. Appl. No. 16/128,450 Office Action dated Dec. 16, 2020. |
| U.S. Appl. No. 16/128,450 Office Action dated Sep. 19, 2019. |
| U.S. Appl. No. 16/129,696 Miscellaneous Communication re: Third Party Submission dated Jul. 3, 2019. |
| U.S. Appl. No. 16/129,696 Office Action dated Apr. 13, 2020. |
| U.S. Appl. No. 16/129,696 Office Action dated Apr. 17, 2019. |
| U.S. Appl. No. 16/129,696 Office Action dated Sep. 19, 2019. |
| U.S. Appl. No. 16/632,827 Office Action dated Feb. 26, 2021. |
| Usman et al. Exploiting the chemical synthesis of RNA. Trends Biochem Sci 17:334-339 (1992). |
| Valtorta et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer 133:1259-1266 (2013). |
| Van Deutekom et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet. 10(15):1547-54 (2001). |
| Van Deutekom et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357(26):2677-2686 (2007). |
| Van Vliet et al. Assessment of the feasibility of exon 45-55 multiexon skipping for duchenne muscular dystrophy. BMC Medical Genetics 9:105 (2008). |
| Verma et al. Modified oligonucleotides: synthesis and strategy for users. Annu Rev Biochem 67:99-134 (1998). |
| Walker et al. Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Pharmaceutical research 12(10):1548-1553 (1995). |
| Ward et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341(6242):544-546 (1989). |
| Watts et al. Chemically modified siRNA: tools and applications. Drug Discov Today 13(19-20):842-855 (2008). |
| Weiner. Liposomes as a Drug Delivery System. Drug Develop Ind Pharm 15:1523 (1989). |
| Wigler et al. Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell 11:223-232 (1977). |
| Wigler et al. Transformation of mammalian cells with an amplifiable dominant-acting gene. PNAS USA 77:3567-3570 (1980). |
| Winkler. Oligonucleotide conjugates for therapeutic applications. Ther Del 4(7):791-809 (2013). |
| Wong et al. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid Ther 22(6):380-390 (2012). |
| Wu et al. Building complex glycopeptides: Development of a cysteine-free native chemical ligation protocol. Angew. Chem. Int. Ed. 45:4116-4125 (2006). |
| Wu et al. Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res 35(15):5182-5191 (2007). |
| Wu et al. Delivery systems for gene therapy. Biotherapy 3:87-95 (1991). |
| Wu et al. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. PNAS USA 105(39):14814-14819 (2008). |
| Wu et al. Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag. PNAS USA 106(9):3000-3005 (2009). |
| Xu et al. Delivery systems for siRNA drug development in cancer therapy. Asian Journal of Pharmaceutical Sciences 10(1):1-12 (2015). |
| Yessine et al. Characterization of the membrane-destabilizing properties of different pH-sensitive methacrylic acid copolymers. Biochimica et Biophysica Acta 1613:28-38 (2003). |
| Yuan et al. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov 4(10):1182-1197 (2014). |
| Zhang et al. A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc. 132(36):12711-12716 (2010). |
| Gooding et al. Oligonucleotide conjugates—Candidates for gene silencing therapeutics. Eur J Pharm Biopharm. 107:321-40 (2016). |
| U.S. Appl. No. 17/463,473 Office Action dated Dec. 13, 2021. |
| U.S. Appl. No. 17/463,484 Office Action dated Jan. 4, 2022. |
| Aartsma-Rus et al., Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. American Journal of Human Genetics 74(1):83-92 (2004). |
| Alegre et al. Effect of a Single Amino Acid Mutation on the Activating and Immunosuppressive Properties of a “Humanized” OKT3 Monoclonal Antibody. J Immunol 148:3461-3468 (1992). |
| Brain and Development 42:117-123 (2010). |
| Darimont et al. Aug. 2005 Abstract: A novel Antibody-Oligonucleotide Conjugate (AOC) platform enables efficient regulation of muscle targets in mice. Journal Of Cachexia, Sarcopenia And Muscle 8:999-1080 (2017). |
| Echigoya et al. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Mol Ther 25(11):2561-2572 (2017). |
| Ferreiro et al. Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion. Muscle Nerve 39:239-243 (2009). |
| Idusogie, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. Apr. 15, 2000;164(8):4178-84. |
| Kaneko et al. Optimizing Therapeutic Antibody Function: Progress With Fc Domain Engineering. Biodrugs 25(1):1-11 (2011). |
| Lazar et al. Engineered antibody Fc variants with enhanced effector function. PNAS USA 103(11):4005-10 (2006). |
| Lee et al. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression. Methods Mol Biol. 1828:141-150 (2018). |
| Moore et al. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mAbs 2(2):181-189 (2010). |
| Nakamura et al. Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene. J. Clin. Neurosci. 15:757-763 (2008). |
| Natsume et al. Engineered Antibodies of IgG1/IgG3 Mixed Isotype With Enhanced Cytotoxic Activities. Cancer Res 68(10):3863-72 (2008). |
| PCT/US2020/029731 International Invitation to Pay Additional Fees dated Aug. 3, 2020. |
| PCT/US2020/029731 International Search Report and Written Opinion dated Oct. 6, 2020. |
| Shields et al. High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR. J Biol Chem 276(9):6591-6604 (2001). |
| Stavenhagen et al. Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization. Adv Enzyme Regul. 48:152-64 (2008). |
| Stavenhagen et al. Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fcγ Receptors. Cancer Res 67(18):8882-91 (2007). |
| Suzuki et al. Endogenous Multiple Exon Skipping and Back-Splicing at the DMD Mutation Hotspot. Int J Mol Sci. 17(10):1722 (2016). |
| U.S. Appl. No. 16/129,696 Office Action dated Dec. 14, 2020. |
| U.S. Appl. No. 16/129,696 Office Action dated May 26, 2021. |
| U.S. Appl. No. 16/649,572 Miscellaneous Communication re: Third Party Submission dated Mar. 19, 2021. |
| U.S. Appl. No. 16/649,572 Office Action dated Feb. 22, 2023. |
| Xia et al. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res 24(12):2309-16 (2007). |
| Number | Date | Country | |
|---|---|---|---|
| 20210395741 A1 | Dec 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16632827 | US | |
| Child | 17466833 | US |
